Experts from the drug and biotech industry along with academic researchers are conscious of the fact that trial methodology cannot continue on...

ONLINE, ONLINE, October 22, 2013 /EINPresswire.com/ -- The concept of a clinical trial is inconsistent with personalised medicine and lacks clarity. Experts from the drug and biotech industry along with academic researchers are conscious of the fact that trial methodology cannot continue on as before and needs in-depth modification.

The traditional clinical trial model fails due to the tendency of diseases such as cancer to be multifactorial in nature, with molecular and phenotypic differentiation. Clinical trials for personalised medicine must be designed to be able to build assurance in the predictability of outcomes – and to do this with very small test populations. Moreover, there still remain several emerging questions related to donor recruitment, e.g., lack of universal access to patient-derived data in the form of biospecimen, that need to be answered.

What is the future of clinical trial designs for personalised medicine? Do clinical trials even work? Is there any real future perspective, or are the diseases of individuals so particular that testing new medicines in broad groups could prove inefficient and unreliable?

This is why Kakushin is organizing a web conference New Perspectives in Clinical Trial Design for Personalized Medicine with the topics covered:

- Impact, challenges, and obstacles related to adaptive design methods (statistical, regulatory perspective)
- The Hunt for Better Biomarkers,The Challenges of Biomarker-Based Clinical Trials-Sample/data sourcing becomes a big issue
- Virtual clinical trials: identification and recruitment of the trial participants-integration of basic PMx tools into every day life

Find more details at http://pharma.kakushinwebinars.com/clinical-trial-design-personalised-medicine?utm_source=external&utm_medium=pr&utm_campaign=einnewswire

Peter Kortvel
Kakushin
+421 257 272 184
email us here